Literature DB >> 17264798

Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro.

Keiji Tanimoto1, Mika Kaneyasu, Tatsushi Shimokuni, Keiko Hiyama, Masahiko Nishiyama.   

Abstract

BACKGROUND: The conversion of CPT-11 to its active form, SN-38, by carboxylesterases (CESs) is a critical event in CPT-11-induced cytotoxicity. Among the CESs, CES1 and CES2 probably play a major role in the metabolism, but the functional significance and molecular basis of CES1 on CPT-11 response remain unclear. METHODS AND
RESULTS: We investigated CES1A1 (AB119997) and CES1A2 (AB187225), whose coding sequences were recently registered in GenBank, for CPT-11-induced cytotoxicity, anticipating novel biomarkers of CPT-11 response. Their coding sequences showed high homology, with only four amino acid differences in the N-terminal region, but our sequencing study of the 5' regions revealed that CES1A1 and CES1A2 had distinctive consensus sequences for transcription factors in the regions, implying differences in transcriptional regulation of the genes. We also identified three isoforms of CES1A1 gene--CES1A1a, CES1A1b and CES1A1c--and developed a detection method for CES1A1 and CES1A2 types of mRNA expression. Interestingly, CES1A2 type of mRNA was found to be expressed from both CES1A1b and CES1A1c isoforms and CES1A2, the promoter activity of the former was higher than that of the original CES1A2 gene. Finally, CES1A2 type of mRNA expression correlated with CPT-11 sensitivities of cancer cells.
CONCLUSION: We demonstrated novel sequence structures and a functional role of CES1A genes in CPT-11 responses. We believe that our novel findings will be of key importance in developing a really useful prediction method for CPT-11 chemosensitivity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17264798     DOI: 10.1097/01.fpc.0000230110.18957.50

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  13 in total

1.  The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects.

Authors:  Claus Stage; Gesche Jürgens; Louise Schow Guski; Ragnar Thomsen; Ditte Bjerre; Laura Ferrero-Miliani; Yassine Kamal Lyauk; Henrik Berg Rasmussen; Kim Dalhoff
Journal:  Br J Clin Pharmacol       Date:  2017-02-24       Impact factor: 4.335

Review 2.  Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators.

Authors:  Lucy Her; Hao-Jie Zhu
Journal:  Drug Metab Dispos       Date:  2019-12-23       Impact factor: 3.922

Review 3.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

4.  Regulatory effects of genomic translocations at the human carboxylesterase-1 (CES1) gene locus.

Authors:  Jonathan C Sanford; Xinwen Wang; Jian Shi; Elizabeth S Barrie; Danxin Wang; Hao-Jie Zhu; Wolfgang Sadee
Journal:  Pharmacogenet Genomics       Date:  2016-05       Impact factor: 2.089

5.  CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors.

Authors:  X Wang; G Wang; J Shi; J Aa; R Comas; Y Liang; H-J Zhu
Journal:  Pharmacogenomics J       Date:  2015-06-16       Impact factor: 3.550

6.  Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.

Authors:  Kimie Sai; Yoshiro Saito; Naoko Tatewaki; Masakiyo Hosokawa; Nahoko Kaniwa; Tomoko Nishimaki-Mogami; Mikihiko Naito; Jun-Ichi Sawada; Kuniaki Shirao; Tetsuya Hamaguchi; Noboru Yamamoto; Hideo Kunitoh; Tomohide Tamura; Yasuhide Yamada; Yuichiro Ohe; Teruhiko Yoshida; Hironobu Minami; Atsushi Ohtsu; Yasuhiro Matsumura; Nagahiro Saijo; Haruhiro Okuda
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

7.  Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins.

Authors:  Roger S Holmes; Matthew W Wright; Stanley J F Laulederkind; Laura A Cox; Masakiyo Hosokawa; Teruko Imai; Shun Ishibashi; Richard Lehner; Masao Miyazaki; Everett J Perkins; Phillip M Potter; Matthew R Redinbo; Jacques Robert; Tetsuo Satoh; Tetsuro Yamashita; Bingfan Yan; Tsuyoshi Yokoi; Rudolf Zechner; Lois J Maltais
Journal:  Mamm Genome       Date:  2010-10-08       Impact factor: 2.957

8.  Carboxylesterase 1 (CES1) genetic polymorphisms and oseltamivir activation.

Authors:  Hao-Jie Zhu; John S Markowitz
Journal:  Eur J Clin Pharmacol       Date:  2012-07-31       Impact factor: 2.953

Review 9.  Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review.

Authors:  Stephen Toovey; Craig Rayner; Eric Prinssen; Tom Chu; Barbara Donner; Bharat Thakrar; Regina Dutkowski; Gerhard Hoffmann; Alexander Breidenbach; Lothar Lindemann; Ellen Carey; Lauren Boak; Ronald Gieschke; Susan Sacks; Jonathan Solsky; Ian Small; David Reddy
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

10.  Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system.

Authors:  Gerhard Hoffmann; Christoph Funk; Stephen Fowler; Michael B Otteneder; Alexander Breidenbach; Craig R Rayner; Tom Chu; Eric P Prinssen
Journal:  Antimicrob Agents Chemother       Date:  2009-08-31       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.